Evidence map›Paper›PMID 24962643›Full record

ArticleInflammation2015

Alpha-lipoic acid exerts anti-inflammatory effects on lipopolysaccharide-stimulated rat mesangial cells via inhibition of nuclear factor kappa B (NF-κB) signaling pathway.

Guofu Li, Jiahong Fu, Yang Zhao, Kaiqiang Ji, Ting Luan, Bin Zang

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07736495 (Evaluation of the Protective Effect of Alpha-Lipoic Acid Against 5-Fluorouracil-Induced Oral Mucositis in Colorectal Cancer Patients), which is not on this map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07736495 phase2 / phase3recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluation of the Protective Effect of Alpha-Lipoic Acid Against 5-Fluorouracil-Induced Oral Mucositis in Colorectal Cancer Patients

TypeinterventionalSponsorAin Shams UniversityRan2026 to 2026Enrolled50ConditionsColorectal CancerArmsalpha lipoic acid 600 mg twice daily, Placebo Tablet
3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Alpha-lipoic acid: A promising pharmacotherapy seen through the lens of kidney diseases.Current research in pharmacology and drug discovery · 2024
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Guofu LiDepartment of Critical Care Medicine, Shengjing Hospital, China Medical University, 36 Sanhao Street, Shenyang, 110004, Liaoning Province, People's Republic of China, leeguofu@hotmail.com.
Jiahong Fu
Yang Zhao
Kaiqiang Ji
Ting Luan
Bin Zang
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis is often initiated by invasive infection, characterized by overwhelming induction of pro-inflammatory cytokines. The incidence and mortality of sepsis and the associated development of acute kidney injury (AKI) remain high, and lines of research into potential treatments are needed. This study was conducted to investigate effects of alpha-lipoic acid (ALA) on septic AKI in vitro. ALA of 200 or 400 μM was used to pretreat rat HBZY-1 mesangial cells before commencement of 1 μg/mL lipopolysaccharide (LPS). Our data indicated that ALA pretreatment reduced LPS-stimulated release of inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α), interleukin (IL)-1 beta (IL-1β), as well as IL-6, in HBZY-1 cell supernatant. Moreover, LPS-induced expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) was inhibited by ALA pretreatment, and consequently, the secretion levels of their respective enzymatic products prostaglandin E2 (PGE2) and nitric oxide (NO) were significantly decreased. LPS-enhanced phosphorylation of nuclear factor kappa B (NF-κB) inhibitor alpha (IκBα) and IκB kinase alpha/beta (IKKα/β) and nuclear translocation of NF-κB subunit p65 in HBZY-1 cells were inhibited by ALA pretreatment. Additionally, the NF-κB inhibitor N-acetylcysteine (NAC) exerted similar inhibitory effects as ALA on COX-2 and iNOS expression. In summary, our study demonstrates that ALA mitigates LPS-induced inflammatory responses in rat mesangial cells probably via inhibition of NF-κB signaling pathway, suggesting a therapeutic potential of ALA in AKI related to sepsis.

Indexed as

AcetylcysteineAcute Kidney InjuryAnimalsAnti-Inflammatory AgentsAntioxidantsCell LineCell SurvivalCyclooxygenase 2DinoprostoneI-kappa B KinaseI-kappa B ProteinsInflammationInterleukin-1betaInterleukin-6LipopolysaccharidesMesangial CellsAcetylcysteineAnti-Inflammatory AgentsAntioxidantsChuk protein, mouseCyclooxygenase 2DinoprostoneI-kappa B KinaseI-kappa B ProteinsIL1B protein, mouseInterleukin-1betaInterleukin-6LipopolysaccharidesNF-kappa BNF-KappaB Inhibitor alphaNfkbia protein, mouseNfkbia protein, ratNitric OxideNitric Oxide Synthase Type IIPtgs2 protein, mouseRela protein, mouseThioctic AcidTranscription Factor RelATumor Necrosis Factor-alpha

Identifiers

PMID24962643
OpenAlexW2072305323

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.